.
Clinical data from 2024 and 2025 demonstrate that the CyberKnife Robotic Radiosurgery System provides high rates of local tumor control and survival across various conditions, often with fewer side effects than traditional radiation
Oncology Success Rates
Recent long-term and clinical trial data highlight its efficacy:
Prostate Cancer: 10-year data shows a 93.7% disease-free survival rate for localized prostate cancer. 2024 studies confirm high-risk and recurrent cases can be treated effectively in just 5 days with low toxicity.
Vestibular Schwannoma: A 25-year study reported in 2025 showed an 89.3% local control rate and a 97.1% overall survival rate.
Brain Tumors: General 1-year overall survival for brain tumor patients is approximately 96.8%. New 2024 data indicates it is a safe option for challenging brainstem metastases.
Lung Cancer: Five-year disease-free survival rates for low-risk patients range between 97% and 100%.
Non-Oncological Outcomes
CyberKnife is also utilized for painful neurological conditions:
Trigeminal Neuralgia: 2025 data shows 90% of elderly patients experienced significant pain improvement or elimination.
Spinal Metastases: Achieved a 93.8% local tumor control rate over three years, with 87.5% of patients reporting pain relief.
Operational and Technical Data
Precision: The system maintains sub-millimeter accuracy (<1mm targeting error) by tracking tumor motion in real-time.
Treatment Duration: Most courses are completed in 1 to 5 sessions over 1–2 weeks, compared to 30–40 sessions for conventional therapy.
Side Effects: Clinical data indicates lower incidences of late-grade bladder and bowel toxicities compared to standard linear accelerators.
For more detailed information call the top cancer specialists in Miami at the Cyberknife Center of Miami – The Beam Of Life at 305-279-2900.